Fulton Bank, N.A. Biomarin Pharmaceutical Inc Transaction History

Fulton Bank, N.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 05, 2022	SELL	$74.28 - $92.69 $173,295 - $216,245	-2,333 Closed	0 $0
Q4 2021 Jan 05, 2022	BUY	$71.72 - $91.47 $167,322 - $213,399	2,333 New	2,333 $206,000
Q3 2021 Oct 05, 2021	SELL	$74.77 - $85.47 $311,790 - $356,409	-4,170 Closed	0 $0
Q2 2021 Jul 06, 2021	BUY	$75.51 - $84.79 $24,993 - $28,065	331 Added 8.62%	4,170 $348,000
Q1 2021 Apr 05, 2021	BUY	$74.73 - $90.69 $30,489 - $37,001	408 Added 11.89%	3,839 $290,000
Q4 2020 Jan 07, 2021	BUY	$72.61 - $90.2 $19,096 - $23,722	263 Added 8.3%	3,431 $301,000
Q3 2020 Oct 06, 2020	BUY	$71.87 - $131.03 $37,444 - $68,266	521 Added 19.68%	3,168 $241,000
Q2 2020 Jul 06, 2020	BUY	$79.55 - $124.22 $17,341 - $27,079	218 Added 8.97%	2,647 $326,000
Q1 2020 Apr 03, 2020	BUY	$71.37 - $96.85 $173,357 - $235,248	2,429 New	2,429 $205,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Fulton Bank, N.A., based on Form 13F filings with the SEC.

Stay updated on Fulton Bank, N.A. with notifications on news.